Breaking News

Major new nicotine production facility announced

| December 4, 2014

Two entrepreneurs who launched one of the UK’s first electronic cigarette brands have partnered with a global supplier of pharmaceutical nicotine to build at Liverpool, the UK, Europe’s largest outsourced manufacturing facility for nicotine products, according to a press note issued by Citypress.

David Newns and Chris Lord, who sold their electronic cigarette business C N creative – owner of the Intellicig brand – to British American Tobacco in 2012, have joined forces with Germany-based Contraf-Nicotex-Tobacco GmbH (CNT) to form Nerudia Limited. The business, which is investing £11m into the new facility, will focus on the development, production, testing and regulatory compliance of nicotine products specifically for the electronic cigarette market, supplying brand owners rather than consumers.

The new venture will occupy an 80,000 sq ft facility that was previously purpose built by a pharmaceutical company for the manufacture of inhaled medicines.

The business, which will be fully operational by January, is currently recruiting 30 people and expects to create up to 150 jobs in its first three years of operation.

It has secured its first major manufacturing contract and is said to be in advanced discussions with several other e-cigarette brand suppliers.

Demand for electronic cigarettes, also known as vaporisers, has grown rapidly since their launch just over a decade ago. The global market is now estimated to be worth £1.8 billion, and is growing at 70 percent per year.

“A new EU directive will come into force in 2016 creating a new and welcome regulated environment for e-cigarettes,” said David Newns, CEO of Nerudia. “Many of the requirements of the new regulation surround the ‘quality’ of e-cigarettes and their contents. The knowledge that we have gained over the past six years of working with the UK and other regulators enables us to offer a unique service to help companies through the process of new regulation.

“Our new facility will offer the expanding market a fully-outsourced, best-in-class nicotine product manufacturing service providing e-liquids and capsule filling, thus enabling e-cigarette companies to focus on their sales and marketing in this rapidly growing sector.”

Newns described the growth of the vaporiser market as having been a “modern phenomenon”; but he said that this growth had come with an increasing focus on key areas of product innovation quality and reliability. “This is a fast-moving landscape and few brands can build the capabilities in-house to keep pace,” he said. “Nerudia has been created to offer the market the very latest product innovation, manufacturing technology, testing facilities and compliance procedures, enabling brands to concentrate on what they do best.”

Meanwhile, Torsten Siemann, the managing director of CNT described Nerudia as an exciting opportunity for CNT that would allow it to expand its integrated supply chain further. “In addition to the supply of ultrapure nicotine made in Switzerland, we will be able to support our customers throughout Europe in their quest to comply with the impending EU regulations that will be in force from 2016,” he said. “With Nerudia we will be in the position to offer our tobacco as well as our pharmaceutical customers access to world class innovation and manufacturing expertise in this new and fast moving category.”

CNT is the world’s largest supplier of pharmaceutical grade nicotine and is a global operating company involved in growing, sourcing, developing, processing, extracting and producing a range of agriculturally originated products. Headquartered in Heilbronn, Germany, it has operations in India, South America and Africa. It supplies some of the world’s largest tobacco and pharmaceutical manufacturers with raw materials and processed products.

Non-animal tobacco-testing alternatives to be aired

| December 4, 2014

A PETA International Science Consortium advisor, Joseph Manuppello, will present the ‘Animal Protection Perspective’ at a workshop sponsored by the US Food and Drug Administration (FDA) intended to identify in vitro models and assays for tobacco toxicity testing.

The workshop, Assessment of In Vitro COPD [Chronic Obstructive Pulmonary Disease] Models for Tobacco Regulatory Science, was designed by the non-profit laboratory, the Institute for In Vitro Sciences (IIVS), to bring together experts and participants specifically to address the relevant research goals of the FDA’s Center for Tobacco Products (CTP).

According to IIVS, the research priorities of the CTP include the identification of in vitro models and assays for assessing tobacco constituent or compound hazards and for comparing the respiratory toxicity of different tobacco products.

Areas to be explored during the workshop include:

* Inflammation and Oxidative Stress;

* Ciliary Dysfunction and Ion Transport;

* Goblet Cell Hyperplasia and Mucus Production; and

* Parenchymal/Bronchial Tissue Destruction and Remodeling.

The introductory session will feature speakers from the CTP, R. J. Reynolds, and the PETA International Science Consortium presenting regulatory, industry, and animal protection perspectives.

Manuppello will discuss opportunities for minimizing animal use within the current regulatory environment for tobacco products. “Tobacco products can and must be tested using non-animal testing methods as the standard, and the FDA must exercise its authority to avoid harming animals,” said Manuppello.

The workshop in Bethesda, Maryland, will be held on December 8-10 at the North Bethesda Marriott and Conference Center.

There is more information about non-animal testing methods at the PETA International Science Consortium, Ltd. website.

UK consultation to be held on tobacco industry ‘levy’

| December 4, 2014

The UK Treasury is to launch a consultation on a potential levy on the tobacco industry, according to a story by Jill Treanor for The Guardian.

Although the Chancellor, George Osborne, did not mention the consultation during his autumn statement to MPs on Wednesday, it was included in documents released alongside the statement.

‘Smoking imposes costs on society, and the government believes it is therefore fair to ask the tobacco industry to make a greater contribution,’ Treanor quoted the Treasury as saying.

‘The government will shortly launch a consultation on introducing a levy on tobacco manufacturers and importers.’

Deborah Arnott, the chief executive of Ash, described the announcement of the consultation as “almost like Christmas come early”.

In another Guardian story in September, the UK’s tobacco industry was said to have reacted with ‘fury’ to a plan by the opposition Labour Party leader, Ed Miliband, to impose an additional tax on Britain’s tobacco companies to help pay for National Health Service spending.

Miliband told delegates at the annual party conference in Manchester that it was fair to impose additional costs on an industry that makes “soaring profits on the back of ill health”.

The UK is due to hold a general election on May 7 next year.

Kim Jong Un orders officials to smoke domestic cigarettes

| December 4, 2014
True patriots

True patriots

Calling foreign cigarettes unpatriotic, North Korean leader and smoker Kim Jong Un ordered senior officials to smoke only domestic cigarettes, reports the International Business Times.

It is unclear whether the directive applies also to counterfeit cigarettes made in North Korea with foreign labels.

Earlier this year, a report by the Washington, DC-based Committee for Human Rights in North Korea said that the isolated country manufacturers millions of cartons of cigarettes bearing foreign labels and ships them worldwide to raise hard currency.

‘No evidence for tobacco’s plain packaging position’

| December 4, 2014

Researchers from the University of Bath, in the United Kingdom, found no independent evidence supporting the tobacco industry’s arguments against plain packaging, reports the Jersey Evening Post.

In a study released on Dec. 3, the researcher reviewed 74 pieces of evidence cited by tobacco companies to argue that plain packaging would have negative effects on the economy and fuel illicit trade.

The researchers found that there were no independent, peer-reviewed reports supporting the industry position and that 47 percent of the pieces of evidence reviewed came from reports commissioned by the industry itself or from third parties with financial connections to the industry.

More than two-thirds of the evidence supplied by tobacco companies was just opinion, according to the researchers. It was provided by business or retail organizations with tobacco company members, trade unions with tobacco company employees, and 51 MPs opposed to plain packaging, seven of whom have allegedly accepted industry hospitality.



E-liquids not medicine, says German court

| December 4, 2014

A German court has ruled that the liquids contained in e-cigarettes aren’t medicinal products and can be sold freely, reports the Associated Press

The Federal Administrative Court delivered its verdict Thursday in a case involving a woman who ran an e-cigarette shop in Wuppertal.

City authorities barred her in 2012 from selling liquids containing nicotine in various strengths on the ground that they were pharmaceutical products that weren’t licensed as such and therefore couldn’t be marketed. A lower court ruling went against the plaintiff.

white cloud cigarettes

pattyn banner

itm banner